Maia Biotechnology Insider Bought Shares Worth $299,409, According to a Recent SEC Filing
Stan Smith, Director, on April 25, 2024, executed a purchase for 147,492 shares in Maia Biotechnology (MAIA) for $299,409. Following the Form 4 filing with the SEC, Smith has control over a total of 1
MAIA Biotechnology Announces $1.00 Million Private Placement
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements
NYSE American Net Change Percentage Gainers & Losers
GAINERS COMPANY SYMBOL LAST CHANGE PERCENT VOLUME ------- ------ ---- ------ ------- ------ CPI Aerost
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad
MAIA Biotechnology Boosts CEO Jeffrey Himmelreich's Salary
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
Company recognizes significant support by board members in recent private placement MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
Five independent members of MAIA's Board of Directors purchased shares in the offering MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted
MAIA Biotechnology Announces $1.33 Million Private Placement
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements
MAIA Biotechnology Increased Maximum Aggregate Offering Price Of Shares Of Common Stock, Issuable Under At Market Offering Agreement
MAIA Biotechnology Increased Maximum Aggregate Offering Price Of Shares Of Common Stock, Issuable Under At Market Offering Agreement
CGC, CYTO and IDN Are Among Mid-day Movers
MAIA Biotechnology at Risk of NYSE Delisting Over Equity Shortfalls
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
Dr. Smith has participated in every MAIA funding round MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to Its Scientific Advisory Board
Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing
Director Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA)
Maia Biotechnology Director Buys $8.1k in Company Shares
MAIA Biotechnology up 3%, Raises $2.9MM via Private Placement
MAIA Biotechnology Shares Halted On Code News Pending
MAIA Biotechnology Shares Halted On Code News Pending
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced its participation in the 36th Annual ROTH
PWM, RVSN and AISP Among Pre-market Losers
MAIA Biotechnology, Inc. (MAIA) Receives a Buy From Noble Financial
No Data